tralokinumab
Adbry (tralokinumab) is an interleukin-13 antagonist from LEO Pharma for moderate to severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies. It can be used with or without topical corticosteroids.
This page is based on FDA prescribing information and the EMA medicine record for tralokinumab, cross-checked with DailyMed; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
In atopic dermatitis the immune system keeps sending an inflammatory memo called IL-13 to the skin, and the skin answers with itch, redness, and a leaky barrier. Tralokinumab is a paper shredder shaped exactly for that memo. It destroys IL-13 before the skin can read it, so the itch-scratch cycle calms and the barrier can repair.
In simple terms
Tralokinumab is a monoclonal antibody given by subcutaneous injection that binds the cytokine interleukin-13 and blocks its signalling. IL-13 is a key driver of the inflammation, itch, and skin barrier problems in atopic dermatitis. By neutralising IL-13, tralokinumab reduces these features of the disease in patients aged 12 years and older whose eczema is not adequately controlled with topical prescription treatments.
In depth
Tralokinumab is an interleukin-13 antagonist: a fully human monoclonal antibody that binds IL-13 with high affinity and prevents its interaction with the IL-13 receptor complex, blocking IL-13-mediated signalling. IL-13 is a central cytokine in atopic dermatitis pathophysiology, promoting type 2 inflammation, pruritus, and skin barrier dysfunction. By neutralising IL-13, tralokinumab reduces the signs and symptoms of moderate to severe atopic dermatitis in adults and adolescents from age twelve, and it may be used with or without topical corticosteroids.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How tralokinumab, a fully human antibody, neutralises IL-13 in atopic dermatitis
- In atopic dermatitis the immune system keeps sending an inflammatory memo called IL-13 to the skin, and the skin answers with itch, redness, and a leaky barrier.
- Tralokinumab is an interleukin-13 antagonist: a fully human monoclonal antibody that binds IL-13 with high affinity and prevents its interaction with the IL-13 receptor complex, blocking IL-13-mediated signalling.
- IL-13 is a central cytokine in atopic dermatitis pathophysiology, promoting type 2 inflammation, pruritus, and skin barrier dysfunction.
- By neutralising IL-13, tralokinumab reduces the signs and symptoms of moderate to severe atopic dermatitis in adults and adolescents from age twelve, and it may be used with or without topical corticosteroids.
Target: Interleukin-13 (IL-13)
A cytokine that drives the itch, inflammation, and skin barrier disruption of atopic dermatitis; neutralising it interrupts a central signal of the disease.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- For the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, with or without topical corticosteroids
Approved uses in European Union
EMA- For the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy
Official sources
The statements on this page trace back to these records.
- Adtralza (tralokinumab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: ADBRY (tralokinumab) official US label
U.S. National Library of Medicine, DailyMed
- U.S. Food and Drug Administration: tralokinumab prescribing information
U.S. Food and Drug Administration
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.